GSK Pauses Development of Herpes Vaccine After Phase II Trial Fails to Show Efficacy
GSK’s herpes vaccine fails phase II efficacy, halts progress but continues safety monitoring.
GSK plc has announced that its phase II data analysis for
the HSV vaccine candidate, GSK3943104, from the TH HSV REC-003 trial, did not
meet its primary efficacy goal. This study was designed to test the potential
clinical benefits of the early-stage herpes simplex virus vaccine. As a result,
the vaccine candidate will not move forward to phase III trials. However, no
safety concerns were found during the trial.
While GSK will continue monitoring for routine safety and
follow-up data to better understand recurrent genital herpes, the company
remains committed to innovation in this space. GSK aims to review all collected
data to guide future research and the development of its herpes simplex virus
program. The need for novel solutions to manage genital herpes remains a
priority for the company.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Mehr aus Pharma News
Alle Beiträge →
Medicus Pharma reicht Phase‑2b/3‑Protokoll für Teverelix bei der FDA ein
Fresenius Kabi erhält FDA-Warnschreiben nach Fehlern bei der Untersuchung aseptischer Verarbeitung in der Anlage Melrose Park
Discussion